Abstract:Rituximab is a human-mouse chimeric monoclonal antibody synthesized using genetic engineering technology and exert pharmacological effects by specifically binding to the transmembrane protein CD20 on the surface of B cells. The clinical therapeutic effect of rituximab is significant, but its pharmacological mechanism is complex, the pharmacokinetics/pharmacodynamics (PK/PD) presents as nonlinear models and is highly variable, which brings great variability and uncertainty to the effectiveness and safety of rituximab in clinic, so individualized therapy needs to be implemented to improve the rationality of medication. At present, rituximab has the basic conditions for therapeutic drug monitoring (TDM), such as detection technology of blood drug concentration, tumor biomarkers, and related genetic polymorphisms. Using these technologies, combined with comprehensive analysis of factors such as disease diagnosis, population specificity, route of administration, and drug interactions, the PK/PD model of rituximab can be constructed to predict the efficacy, toxicity, and drug resistance. It is of great significance for pharmacists to participate in the individualized rituximab treatment and carry out TDM, which can provide safer and more effective individualized treatment for patients.